Six-month oral treatment for rifampin-resistant tuberculosis
Treatments studied
Part of Infections clinical trials.
This study tests a 6-month treatment with four oral medicines (bedaquiline, delamanid, linezolid, and levofloxacin) for people whose TB is resistant to rifampin. The goal is to see if this all-pill combination is safe and effective in treating this difficult type of TB.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your TB is resistant to the medicine rifampin (also called RIF), a common TB drug.
- You have not taken bedaquiline, delamanid, linezolid, or levofloxacin for more than 4 weeks in the past.
- You have had a positive TB culture (sputum test) within the last month, and no effective TB treatment during that time.
- You do not have serious heart problems or an abnormal heart rhythm on an ECG.
- You are not pregnant or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a shorter six-month treatment for tuberculosis that is resistant to rifampicin, a common antibiotic. The goal is to make treatment easier and possibly safer while still being effective.
This trial tests a shorter treatment for tuberculosis (TB) using a combination of three medicines: bedaquiline, moxifloxacin, and pyrazinamide. If you have TB in your lungs, this could be a way to treat it more quickly than the standard longer course.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
This trial tests a new 6-month treatment for people with multidrug-resistant tuberculosis (MDR-TB). It aims to see if this shorter treatment works well and can be used in France, offering a quicker option for recovery.
This study tests a shorter treatment for drug-resistant tuberculosis (TB) using a medicine called pretomanid. It aims to see if a shorter course of treatment can effectively cure TB that doesn't respond to a standard drug called rifampicin, reducing treatment time for patients.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
Hear when a new Treatment Duration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.